I'm delighted. The per-share offer was laughably low. It needed to be $1.75 per share at least to be worth considering. The purported cost savings were negligible. To accept the offer would have been a complete dereliction of the board's responsibilities toward us.
PTX This rare type of lymphoma ruins the body – so do existing treatments. Prescient could have a solution